{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"545","upperLimit":"718","value":"626"},{"comment":"GMT value was \\<7 milli Merck U/mL","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Anti-HPV Type 11 antibodies were measured by cLIA. The seropositive cut-off threshold for this assay is defined as 16 milli Merck U/mL.","dispersionType":"95% Confidence Interval","groups":[{"description":"GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A","id":"OG000","title":"GARDASIL 9 to 26 Years Old"},{"description":"Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A","id":"OG001","title":"Placebo 9 to 12 Years Old"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants analyzed included those who received all 3 vaccinations in study Phase A and provided a sample for Month 7 serology testing. This analysis pooled results for participants receiving GARDASIL and compared these with results for participants receiving placebo.","reportingStatus":"POSTED","timeFrame":"Month 7 (1 month postdose 3 in study Phase A)","title":"GMT of Anti-HPV Type 11 Antibody","type":"SECONDARY","unitOfMeasure":"milli Merck U/mL"}